A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research

Enzalutamide was the first novel androgen receptor signaling inhibitor to demonstrate an overall survival benefit in non-metastatic and metastatic castration-sensitive prostate cancer (CSPC). It has emerged as one of the most commonly prescribed oral prostate cancer therapies (ARSI) by medical oncol...

Descripción completa

Detalles Bibliográficos
Autores principales: Laccetti, Andrew L, Morris, Michael J, Kantoff, Philip W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778386/
https://www.ncbi.nlm.nih.gov/pubmed/33402834
http://dx.doi.org/10.2147/OTT.S242921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778386/
https://www.ncbi.nlm.nih.gov/pubmed/33402834
http://dx.doi.org/10.2147/OTT.S242921

Ejemplares similares